The imaging showed extensive cerebral venous sinus thrombosis, a rare form of stroke in which the veins that drain blood from the brain become occluded by clot. CVST accounts for only about 0.5 to 3 percent of all cerebrovascular events, but it disproportionately strikes younger people, particularly women. In this patient, the thrombosis was not confined to one vessel. The superior sagittal sinus, both transverse sinuses, both sigmoid sinuses, and the right internal jugular vein were all involved, effectively shutting down the supratentorial venous drainage system. Even more ominously, the deep venous system, including the internal cerebral veins and the vein of Galen, was thrombosed as well.

Deep venous involvement matters because those vessels drain structures that have almost no collateral blood supply: the thalami, basal ganglia, hypothalamus, and periventricular white matter. When congestion builds in these territories, venous infarction can develop rapidly and carries high morbidity and mortality. Magnetic resonance imaging in this patient confirmed exactly that pattern. T2-weighted and FLAIR sequences showed bilateral thalamic hyperintensity with periventricular edema, and diffusion-weighted imaging demonstrated restricted diffusion in both thalami, the radiological signature of acute venous infarction. Magnetic resonance venography showed absent or markedly reduced flow through the major sinuses, with prominent cortical collaterals suggesting the brain was desperately rerouting its venous outflow.

Complicating the picture further was obstructive hydrocephalus, a rarely reported consequence of CVST. The noncontrast CT scan showed mild dilatation of the lateral ventricles and prominence of the temporal horns, along with a hyperdense cord sign along the superior sagittal sinus, a classic marker of acute sinus thrombosis. Two mechanisms can drive ventricular enlargement in this setting. Elevated venous sinus pressure can impair cerebrospinal fluid resorption across the arachnoid granulations by altering the pressure gradient, while venous congestion and edema in the thalami and adjacent periventricular structures can physically obstruct cerebrospinal fluid pathways. The authors of the report note that their imaging could not pinpoint a single anatomical obstruction site, so the hydrocephalus was considered likely multifactorial rather than attributable to one definitively demonstrated blockage.

The initial misdiagnosis is perhaps the most instructive element of the case. Idiopathic intracranial hypertension and CVST share strikingly similar presentations: progressive headache, vomiting, visual disturbance, and raised opening pressure on lumbar puncture. The key clinical discriminator is the response to treatment. Acetazolamide typically improves idiopathic intracranial hypertension, whereas untreated CVST worsens over time as the thrombus propagates, potentially leading to venous infarction, hydrocephalus, and neurological deterioration. Plain CT can miss venous sinus thrombosis in up to a third of cases, which is why recent recommendations urge that patients with suspected idiopathic intracranial hypertension be screened with MRI and magnetic resonance venography as part of the diagnostic workup. In this patient, progressive symptoms despite acetazolamide therapy were the crucial clue that prompted advanced imaging and the correct diagnosis.

Once the thrombosis was identified, the team turned to the question of why it had happened. Her complete blood count revealed persistent, marked thrombocytosis, with platelet counts repeatedly measured at 1140 × 10^9 per liter, roughly four times the upper limit of normal. A peripheral blood smear showed large platelets, and a bone marrow biopsy demonstrated hypercellularity with megakaryocytic hyperplasia. Molecular testing identified the JAK2 V617F mutation with a variant allele frequency of 14 percent, while CALR and MPL variants and BCR::ABL1 transcripts were absent. The diagnosis was essential thrombocythemia, a myeloproliferative neoplasm in which the bone marrow produces excessive, functionally abnormal platelets.

The JAK2 V617F mutation, present in roughly half to sixty percent of essential thrombocythemia patients, activates the JAK-STAT signaling pathway, driving platelet overproduction and producing platelets that are prone to inappropriate activation. Beyond thrombocytosis, the mutation contributes to endothelial dysfunction, leukocyte activation, and chronic inflammation, all of which amplify thrombotic risk. The result is a hypercoagulable state capable of producing clots at unusual arterial and venous sites. Venous thromboembolism is a recognized complication of essential thrombocythemia, but cerebral venous sinus thrombosis remains a rare manifestation, and the combination of extensive CVST, obstructive hydrocephalus, and JAK2-positive essential thrombocythemia has seldom been described together in a single patient. Current guidelines therefore recommend evaluating for underlying myeloproliferative neoplasms, including JAK2 mutation testing, in any patient with CVST who has no obvious provoking factor.

Treatment proceeded on two fronts. Immediate anticoagulation with low-molecular-weight heparin, enoxaparin 80 milligrams, was initiated on 21 April 2026, and later transitioned to the oral factor Xa inhibitor apixaban at 5 milligrams twice daily in May 2026. Given the extent of the thrombosis and the persistent prothrombotic risk posed by the underlying blood disorder, long-term anticoagulation was deemed appropriate. Cytoreductive therapy with pegylated interferon alfa was also started to bring the platelet count under control, a choice the report highlights as particularly suitable for women of childbearing age because of its disease-modifying potential. A multidisciplinary team spanning neurology, hematology, radiology, and ophthalmology managed the case, with ophthalmological assessment confirming bilateral papilledema and continuous intracranial pressure monitoring instituted. Notably, the hydrocephalus was managed without neurosurgical cerebrospinal fluid diversion; the patient improved with treatment directed at the thrombosis and the hematological disease, underscoring that management must be individualized to neurological status and imaging progression, while recognizing that deterioration may still demand urgent surgery.

The outcome was striking. By a follow-up visit on 2 June 2026, the patient had improved clinically and her platelet count had fallen to 355 × 10^9 per liter, with hemoglobin of 124 grams per liter, hematocrit of 0.41 liters per liter, and a white cell count of 5.6 × 10^9 per liter. Follow-up magnetic resonance venography demonstrated partial recanalization of the right transverse sinus and the posterior portion of the superior sagittal sinus, though recanalization remained incomplete. Susceptibility-weighted imaging showed blooming in the left basal ganglia, suggestive of residual blood products, but no clinically significant bleeding complication occurred during anticoagulation, and no new thrombotic events were observed on subsequent follow-up. The patient remains under combined neurological and hematological care.

The authors are careful to note the limitations inherent in a single-patient report: the temporal relationship and biological plausibility linking JAK2-positive essential thrombocythemia to this catastrophic venous thrombosis are strong, but causality cannot be proven, and generalizability is limited. Still, the clinical lessons are clear. Worsening symptoms in a patient labeled with idiopathic intracranial hypertension should trigger urgent magnetic resonance venography, because delayed diagnosis of CVST allows thrombus propagation with potentially fatal consequences. Once CVST is confirmed, a thorough workup for hidden prothrombotic disorders, including myeloproliferative neoplasms, is essential, since identifying an underlying condition fundamentally changes long-term management. The case also adds to the sparse literature on hydrocephalus as a complication of cerebral venous thrombosis and stands as a reminder that a young brain, given early diagnosis and coordinated multidisciplinary care, can recover even from near-complete occlusion of its venous drainage system.

Subject of Research: Cerebral venous sinus thrombosis with obstructive hydrocephalus caused by undiagnosed JAK2 V617F-positive essential thrombocythemia

Article Title: Extensive Cerebral Venous Sinus Thrombosis With Obstructive Hydrocephalus in a Young Female With Underlying Essential Thrombocythemia: A Case Report

Article References: Nafea, S., Farooq, T., Taher, M. A., Barros, A., Soe, K. N., Ali, F., & Thomas, K. (2026). Extensive Cerebral Venous Sinus Thrombosis With Obstructive Hydrocephalus in a Young Female With Underlying Essential Thrombocythemia: A Case Report. Clinical Case Reports, 14(10), Article e73669. https://doi.org/10.1002/ccr3.73669

Image Credits: AI Generated

DOI: 10.1002/ccr3.73669

Keywords: cerebral venous sinus thrombosis, essential thrombocythemia, JAK2 V617F, obstructive hydrocephalus, myeloproliferative neoplasm, idiopathic intracranial hypertension, venous infarction, anticoagulation, pegylated interferon alfa, magnetic resonance venography, thalamic infarction, thrombocytosis

The Innovative Project Award provides $200,000 over two years and is deliberately designed to back high-risk, high-reward science. Eligible projects spanned the full breadth of biomedical inquiry, from basic laboratory studies of cells and molecules to clinical investigations and population health research, and applicants could propose work across the entire human lifespan, from children and adolescents through middle age and late life. The prioritization of innovation over incremental safety reflects a conscious strategy by both societies: rather than extending established research programs, they wanted to seed ideas that conventional funding mechanisms might consider too speculative, but that could open entirely new avenues for preventing stroke and heart disease in people living with chronic headache disorders.

This year’s co-funded award goes to Juliana Navia Pelaez, Ph.D., an assistant professor at St. Louis University School of Medicine in St. Louis, Missouri, for a project titled “Neurogenic Priming of Perivascular Macrophages by Migraine-Associated Peptides Increases Stroke Risk.” Her work targets a question that has long puzzled clinicians: why some people who suffer from migraine face a higher risk of stroke. Researchers have traditionally concentrated on the blood vessels themselves, since during a migraine attack these vessels may tighten, swell, or alter the way blood moves through them. But attention is now shifting toward another, less obvious player — the brain’s own resident immune cells, which stand guard along the vessels and help protect neural tissue from injury.

Pelaez’s central hypothesis is that repeated migraine attacks may push these vascular immune cells into a state of chronic overactivation. “If migraines happen over and over, these immune cells might stay ‘on’ for too long. When this happens, they might accidentally make the blood vessels weaker,” Pelaez said. “If the vessels get weaker, the brain might have a harder time protecting itself from a stroke.” In practical terms, the project will map which signals released during a migraine activate these brain immune cells, and then compare how the cells respond to a subsequent stroke in animals that have experienced migraine-like events versus those that have not. The comparison is designed to isolate the specific contribution of migraine biology to stroke vulnerability, rather than attributing everything to shared risk factors such as hypertension or smoking.

The translational implications could be considerable. “If our idea is right,” Pelaez added, “this could help scientists find new ways to prevent strokes in people with chronic migraine, maybe by calming these overactive brain cells or blocking the signals that bother them.” Such a strategy would represent a fundamentally different approach to stroke prevention in this population. Instead of managing vascular risk factors after the fact, clinicians might one day intervene directly on the neuroimmune signaling cascade that links repeated migraine attacks to cumulative vessel damage — a possibility that could reshape how neurologists and cardiologists jointly manage patients with frequent or chronic migraine.

The Heart Association’s three additional awards extend the same investigative ambition across distinct mechanistic frontiers. The first goes to Andrea M. Harriott, M.D., Ph.D., an assistant professor in neurology at Massachusetts General Hospital in Boston, for a study titled “The Impact Of Cortical Spreading Depolarizations On Endothelial Phenotype, Neovascularization, and Collateral Remodeling.” Migraine with aura has long been epidemiologically linked to stroke and heart attack, and earlier thinking held that this association might simply reflect an elevated burden of conventional risk factors among people with aura. Harriott’s project will test a more direct possibility: that the long-term exposure to the mechanisms underlying migraine aura — cortical spreading depolarizations, waves of altered electrical and metabolic activity that sweep across the brain — causes lasting structural and functional harm to cerebral blood vessels. Her team will examine protein-level changes in the cells lining vessel walls, the formation of new blood vessels, and the remodeling of collateral circulation that the brain relies on when its primary supply routes are compromised.

The second award supports Matthew T. Bender, M.D., an associate professor at the University of Rochester in Rochester, New York, whose project, “Defining The Glymphatic-Hemodynamic Axis In IIH: A Novel Multi-Scale Quantitative MRI Framework,” addresses idiopathic intracranial hypertension, or IIH. This headache disorder disproportionately affects overweight women of childbearing age, and clinicians believe it arises from elevated pressure inside the skull driven by excess cerebrospinal fluid. Recent evidence, however, suggests the disorder may also involve dysfunction of the brain’s waste clearance network, known as the glymphatic system. Bender’s team will develop a new magnetic resonance imaging framework capable of visualizing both the glymphatic system and cerebral blood flow without contrast dye or invasive procedures. By scanning IIH patients before and after venous stenting — a procedure that opens narrowed veins draining the brain — the researchers hope to determine how restoring venous outflow affects waste clearance and hemodynamics, potentially establishing imaging markers that could guide treatment decisions.

The third award funds Neil Dani, Ph.D., an assistant professor at Vanderbilt University in Nashville, Tennessee, for “Illuminating Nociceptive And Analgesic Mechanisms Of Choroid Plexus In Migraine And Obesity Models.” Dani’s work responds to the rising prevalence of obesity-related migraine, a clinically important overlap given that both conditions share inflammatory signaling pathways. His focus is the choroid plexus, a small structure inside the brain’s ventricles that produces cerebrospinal fluid and acts as a highly regulated interface, or gate, between the body and the central nervous system. The working hypothesis is that inflammatory signals generated in the body during obesity may travel through the cerebrospinal fluid via the choroid plexus, sensitizing pain circuits and increasing migraine frequency or severity. The project will characterize inflammation patterns in this structure, identify cellular rewiring and immune signaling changes associated with obesity and migraine, and test whether clinically approved drugs — including acetazolamide, a long-standing medication already used in related contexts — can reduce both swelling and pain signaling in experimental models.

Taken together, the four projects sketch a research landscape in which headache disorders and vascular medicine are no longer treated as separate silos. Each award interrogates a different node of the heart-brain axis: immune cells that patrol cerebral vessels, the electrical storms of migraine aura and their vascular aftermath, the interplay of intracranial pressure and brain waste clearance, and the inflammatory crosstalk between metabolism, body-wide immune signaling, and pain. The funders emphasize that these efforts demonstrate the shared commitment of the American Headache Society and the American Heart Association to advancing brain health research, and the co-funding structure itself may prove as influential as the science it supports, encouraging cross-disciplinary training, shared patient cohorts, and unified endpoints across neurology and cardiology.

The initiative also sits within a far larger funding tradition. Supporting scientific research and discovery through programs of this kind is a cornerstone of the century-old American Heart Association’s lifesaving mission. Since 1949, the Association has invested more than $6.3 billion in cardiovascular, cerebrovascular, and brain health research, making it the single largest non-profit, non-governmental supporter of heart and brain health research in the United States. Officials note that knowledge generated through this funding continues to save lives and directly affect millions of people across the country and around the world. For the millions who live with migraine and other headache disorders — and for the clinicians who care for them — the new awards offer something more immediate than long-term promise: a concrete, funded research agenda that treats the pounding in the head and the health of the heart and brain’s vessels as inseparable parts of the same biological story.

Subject of Research: Funded research projects investigating the links between migraine, headache disorders, and cardiovascular and cerebrovascular health

Article Title: New scientific research projects study heart/brain connection to migraines, headaches

Article References: New scientific research projects study heart/brain connection to migraines, headaches. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: migraine, stroke, American Heart Association, American Headache Society, cerebrovascular health, cortical spreading depolarization, idiopathic intracranial hypertension, glymphatic system, choroid plexus, perivascular macrophages, obesity-related migraine, research funding